Article
Oncology
Hae Jin Cho, Soon Auck Hong, Daeun Ryu, Sook-Hee Hong, Tae-Min Kim
Summary: This study aims to discover and characterize novel subtypes of small cell lung cancer (SCLC) and explore their relationship with existing subtypes. SCLC-M (mesenchymal) tumors were identified as distinct from SCLC-I (inflamed) tumors. SCLC-M tumors display elevated epithelial-to-mesenchymal transformation (EMT) activity and low anticancer immune activity, resulting in unfavorable clinical outcomes. These tumors account for approximately 5% of primary SCLC tumors and should be considered in the clinical management of SCLC.
Article
Oncology
Silvia Novello, Dariusz M. Kowalski, Alexander Luft, Mahmut Gumus, David Vicente, Julien Mazieres, Jeronimo Rodriguez-Cid, Ali Tafreshi, Ying Cheng, Ki Hyeong Lee, Alexander Golf, Shunichi Sugawara, Andrew G. Robinson, Balazs Halmos, Erin Jensen, Paul Schwarzenberger, M. Catherine Pietanza, Luis Paz-Ares
Summary: This study provides five-year efficacy and safety outcomes for the treatment of previously untreated metastatic squamous non-small cell lung cancer patients. The results show that pembrolizumab plus chemotherapy significantly improves overall survival and progression-free survival compared to placebo plus chemotherapy. This study demonstrates that pembrolizumab plus chemotherapy is a first-line treatment option for metastatic squamous NSCLC regardless of programmed death ligand 1 expression.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Oncology
Marina C. Garassino, Shirish Gadgeel, Giovanna Speranza, Enriqueta Felip, Emilio Esteban, Manuel Domine, Maximilian J. Hochmair, Steven F. Powell, Helge G. Bischoff, Nir Peled, Francesco Grossi, Ross R. Jennens, Martin Reck, Rina Hui, Edward B. Garon, Takayasu Kurata, Jhanelle E. Gray, Paul Schwarzenberger, Erin Jensen, M. Catherine Pietanza, Delvys Rodriguez-Abreu
Summary: This study presents the 5-year outcomes of the KEYNOTE-189 study, which included previously untreated metastatic nonsquamous non-small-cell lung cancer patients. The results show that treatment with pembrolizumab plus pemetrexed-platinum significantly improves overall survival and progression-free survival compared to placebo plus pemetrexed-platinum. These data continue to support pembrolizumab plus pemetrexed-platinum as a standard of care for previously untreated metastatic non-small-cell lung cancer patients.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Review
Immunology
Ding-Yu Rao, De-Fa Huang, Mao-Yan Si, Hua Lu, Zhi-Xian Tang, Zu-Xiong Zhang
Summary: As an important mediator of information transfer between cells, exosomes play a unique role in regulating tumor growth, supporting vascular proliferation, tumor invasion, and metastasis. Exosomes can be used as a potential tool for non-invasive liquid biopsy due to their presence in various body fluids. This study reviews the role of exosomes in liquid biopsy, tumor microenvironment formation, and epithelial-mesenchymal transition in non-small cell lung cancer (NSCLC). It also discusses the occurrence of EGFR+ exosomes and the role of exosomes and their contents in non-invasive detection and potential therapeutic targets in EGFR-mutated lung cancer.
FRONTIERS IN IMMUNOLOGY
(2023)
Review
Medicine, General & Internal
Min Yi, Ting He, Kaijin Wang, Yonggang Wei
Summary: This study compared the efficacy and safety of gefitinib in combination with chemotherapy versus gefitinib alone in patients with advanced Non-Small Cell Lung Cancer (NSCLC) through a meta-analysis of clinical studies. Results showed that the combination therapy was more effective in improving objective response rate, disease control rate, progression-free survival, and overall survival compared to gefitinib alone. However, the combination therapy also had a higher risk of complications. These findings suggest that the combination therapy can provide better outcomes for patients with advanced NSCLC.
Article
Oncology
Mohammad Aarif Siddiqui, Paradesi Naidu Gollavilli, Vignesh Ramesh, Beatrice Parma, Annemarie Schwab, Maria Eleni Vazakidou, Ramakrishnan Natesan, Ozge Saatci, Ida Rapa, Paolo Bironzo, Harald Schuhwerk, Irfan Ahmed Asangani, Ozgur Sahin, Marco Volante, Paolo Ceppi
Summary: The study identified a functional correlation between thymidylate synthase (TS), EMT, chemotherapy and metastasis in non-small cell lung cancer (NSCLC), establishing TS as a potential therapeutic marker. Further experiments revealed that TS may influence the occurrence and development of NSCLC by regulating EMT transcription factors and effectors.
BRITISH JOURNAL OF CANCER
(2021)
Article
Medicine, General & Internal
Heather Wakelee, Moishe Liberman, Terufumi Kato, Masahiro Tsuboi, Se-Hoon Lee, Shugeng Gao, Ke-Neng Chen, Christophe Dooms, Margarita Majem, Ekkehard Eigendorff, Gaston L. Martinengo, Olivier Bylicki, Delvys Rodriguez-Abreu, Jamie E. E. Chaft, Silvia Novello, Jing Yang, Steven M. M. Keller, Ayman Samkari, Jonathan D. D. Spicer
Summary: Among patients with resectable early-stage NSCLC, perioperative pembrolizumab improved event-free survival, major pathological response, and pathological complete response. The addition of pembrolizumab to neoadjuvant chemotherapy followed by surgery showed significant benefits compared to neoadjuvant chemotherapy alone followed by surgery.
NEW ENGLAND JOURNAL OF MEDICINE
(2023)
Article
Multidisciplinary Sciences
Hiroyuki Yamato, Kenji Kimura, Eriko Fukui, Takashi Kanou, Naoko Ose, Soichiro Funaki, Masato Minami, Yasushi Shintani
Summary: This study found that periostin secreted by fibroblasts from IPF patients plays a critical role in promoting the proliferation of NSCLC cells, suggesting targeting periostin could be a potential therapy for NSCLC patients with IPF.
SCIENTIFIC REPORTS
(2021)
Article
Oncology
Sandra Ortiz-Cuaran, Aurelie Swalduz, Jean-Philippe Foy, Solene Marteau, Anne-Pierre Morel, Frederique Fauvet, Genevieve De Souza, Lucas Michon, Maxime Boussageon, Nicolas Gadot, Marion Godefroy, Sophie Leon, Antonin Tortereau, Nour-El-Houda Mourksi, Camille Leonce, Marie Alexandra Albaret, Anushka Dongre, Beatrice Vanbervliet, Marie Robert, Laurie Tonon, Roxane M. Pommier, Veronique Hofman, Valery Attignonf, Sandrine Boyaulta, Carole Audoynaud, Jessie Auclairf, Fanny Bouquetg, Qing Wang, Christine Menetrier-Cauxa, Maurice Perolb, Christophe Cauxa, Paul Hofmand, Sylvie Lantuejoulb, Alain Puisieuxa, Pierre Saintigny
Summary: Epithelial-to-mesenchymal transition (EMT) is associated with tumor aggressiveness, drug resistance, and poor survival in non-small cell lung cancer (NSCLC) and other cancers. Researchers have found that CD70 and ZEB1 play a key role in immune escape in NSCLC, providing new insights for treating NSCLC through immunotherapy strategies.
EUROPEAN JOURNAL OF CANCER
(2022)
Article
Oncology
Sarah M. Groves, Nicholas Panchy, Darren R. Tyson, Leonard A. Harris, Vito Quaranta, Tian Hong
Summary: This study analyzed the relationship between SCLC subtypes and epithelial to mesenchymal transition (EMT), and found a correspondence between SCLC subtypes and the EMT program. This study provides a basis for further understanding the gene regulatory mechanisms of SCLC tumor plasticity and its applicability to other cancer types.
Article
Oncology
Ran Zhang, Yanxin Cui, Xin Guan, Xiangjun Jiang
Summary: This study suggests that H101 combined with chemotherapy may be a potential therapeutic option for patients with advanced gastric carcinoma, with significantly improved disease control rate, overall response rate, and survival rates compared to chemotherapy or H101 alone. Additionally, complications did not increase with higher doses of treatment. Further prospective studies with proper assessment of toxicity are needed in the future.
FRONTIERS IN ONCOLOGY
(2021)
Article
Endocrinology & Metabolism
Suzheng Zheng, Hai Yu, Xinkai Zheng, U. Tim Wu, Wai-kit Ming, Hui Huang, Jiaxin Song, Xiaoxi Zhang, Jun Lyu, Liehua Deng
Summary: The 5-year relative survival rate of cutaneous melanoma in the US gradually improved from 2004 to 2018, with the greatest improvement seen in amelanotic melanoma. Females had slightly higher survival rates than males, white patients had higher survival rates than nonwhite ones, and urban locations had higher rates of survival from cutaneous melanoma than rural locations. The survival rate was significantly lower for distant metastasis.
FRONTIERS IN ENDOCRINOLOGY
(2023)
Article
Oncology
Xueyan Liang, Xiaoyu Chen, Huijuan Li, Yan Li
Summary: This study assessed the cost-effectiveness of cemiplimab plus chemotherapy compared to chemotherapy alone for the treatment of advanced non-small cell lung cancer (aNSCLC) from the perspective of third-party payers in the United States. The results showed that cemiplimab plus chemotherapy improved efficacy but also increased costs, with an incremental cost-effectiveness ratio (ICER) above the willingness-to-pay (WTP) threshold.
FRONTIERS IN ONCOLOGY
(2023)
Article
Oncology
Eriko Miyawaki, Hirotsugu Kenmotsu, Yasushi Shintani, Ikuo Sekine, Takehito Shukuya, Koichi Takayama, Akira Inoue, Isamu Okamoto, Katsuyuki Kiura, Kazuhisa Takahashi, Nobuyuki Yamamoto, Tomoya Kawaguchi, Etsuo Miyaoka, Ichiro Yoshino, Hiroshi Date
Summary: This study evaluated the efficacy of platinum-doublet chemotherapy as a second-line treatment for patients with unresectable stage III NSCLC following platinum-based chemoradiotherapy. The results showed that platinum-doublet chemotherapy significantly improved overall survival and may be a promising treatment for these patients.
Article
Biochemistry & Molecular Biology
Masashi Kawami, Shinnosuke Takenaka, Mizuki Akai, Ryoko Yumoto, Mikihisa Takano
Summary: The study revealed that in p53-wild type NSCLC cells, miR-34a led to an upregulation of α-SMA, enhanced p53 activity, and promoted cell migration. However, these effects were not significant in p53-deficient cells. Under p53-knockdown condition, miR-34a only upregulated α-SMA, illustrating a close relationship between p53 and miR-34a-induced EMT in p53-wild type NSCLC cells.